Instead, in mice with malignant lung cancer harboring the KRAS p.G12D, PI3K p.H1047R mutations, and TP53-null, Green et colleagues showed a modest growth inhibition using PI3K inhibitors and little or no survival benefit [60]. This evidence concerns the gene TP53 and lung cancer.